Published in final edited form as:

Medchemcomm. 2016 September 1; 7(9): 1789–1792. doi:10.1039/C6MD00237D.

Traceless Solid-Phase α -Hydroxytropolone Synthesis

Michael P. D'Erasmo^{a,b}, Takashi Masaoka^c, Jennifer A. Wilson^d, Errol M. Hunte Jr.^a, John A. Beutler^d, Stuart F. J. Le Grice^c, and Ryan P. Murelli^{a,b}

^aDepartment of Chemistry, Brooklyn College, The City University of New York, Brooklyn, New York, USA

^bPhD Program in Chemistry, The Graduate Center of The City University of New York, New York, NY, USA

^cBasic Research Laboratory, National Cancer Institute, Frederick, MD, USA

^dMolecular Targets Laboratory, National Cancer Institute, Frederick, MD, USA

Abstract

α -Hydroxytropolones are established inhibitors of several therapeutically relevant binuclear metalloenzymes, and thus lead drug targets for various human diseases. We have leveraged a recently-disclosed three-component oxidopyrylium cycloaddition in the first solid-phase synthesis of α -hydroxytropolones. We also showed that, while minor impurities exist after cleavage and aqueous wash, the semi-crude products display activity in HIV RT-associated RNaseH enzymatic and cell-based assays consistent with pure molecules made in solution phase. These proof-of-principle studies demonstrate the feasibility of solid-phase α -hydroxytropolone synthesis and its potential to serve as a powerful platform for α -hydroxytropolone-based drug discovery and development.

α -Hydroxytropolones are a promising class of compounds that have been implicated as therapeutic leads for several human diseases.¹ The activity is often attributed to the three contiguous oxygen atoms, which each have high negative charge character at physiological pH and are well positioned to bind to and inhibit bridged dinuclear metalloenzymes (Figure 1A).² Our lab has been studying an oxidopyrylium cycloaddition/ring-opening strategy that has enabled the synthesis of a variety of structurally diverse α -hydroxytropolones (Figure 1B).^{3,4} Medicinal chemistry studies associated with antibiotic resistance,⁵ hepatitis B,⁶ herpes simplex virus,⁷ and HIV are on-going in our lab that use this strategy. The following describes the adaptation of this method to a solid-support format.

The key advance that has allowed for this modification is a 3-component oxidopyrylium cycloaddition recently described by our lab that facilitates alcohol incorporation into oxabicyclic products (**1a**→**3a**, Scheme 1a).^{8,9} Furthermore, benzyl alcohol-derived oxabicyclic products made through this strategy can be directly converted into α -hydroxytropolones using triflic acid (**3a**→**4g**, Scheme 1a). Given the prevalence of polystyrene-derived solid-supports in chemical synthesis, we became intrigued by the possibility adapting this approach to solid-support using benzyl alcohol on polystyrene (Scheme 1b). A substantial advantage to benzyl alcohol polystyrene as support over widely used derivatives such as Wang resin is that after cleavage, no additional components would

exist in solution, and the process could thus lead to assay-ready compounds without the need for chromatography.

A procedure that we deemed practical for parallel synthesis is described in Figure 2a, and yields are shown in Table 1. First, in a sealed vessel, a solution of **1a** and base was stirred overnight at 60°C in the presence of benzyl alcohol polystyrene beads. We hypothesize that this generates an oxidopyrylium heterodimer (**6c** and/or **6d**, Figure 2b) based upon known rapid dimerization of oxidopyrylium ylides, although additional cross-linking homodimer **6b** cannot be ruled out currently.^{3a} Following the overnight stirring, alkynes were added, and the reactions were heated to 100°C to facilitate the *on-bead* cycloaddition (see Table 1 for results). In instances in which the alkynes were liquids, it was advantageous to remove the solvent and its solutes prior to addition of alkyne. Solid alkyne was directly added to the reaction without removing the solvent and solutes. Optimal cycloaddition reaction times were dependent upon reactivity of the alkyne, and insufficient reaction times led to increased amounts of allomaltol (**7**). Reactions with electronically poor ynones and propiolates were generally complete within 2 hours, whereas aromatic alkynes took ~5 hours to maximize yields. Aside from allomaltol and trace baseline impurities, the only other significant byproducts occasionally observed were furan impurities (**8a–i**), which, as expected, were the major product when dimethylacetylene dicarboxylate was used (**8j**, entry 20).^{3b}

Between 1–5 mg of various α -hydroxytropolones were made from 33 mg of the benzyl alcohol polystyrene and 50 mg of the oxidopyrylium salt, or approximately 5–10% yield based upon the polystyrene resin (Table 1). The greatest mass used was the alkyne which, although 400 mg – 500 mg was needed, is readily available in large quantities. Most importantly, though, the process is highly time efficient by circumventing the need for chromatography. As many as 8 reactions have been run in parallel in a single 24 hour period during the course of our studies, and enough material was generated to confirm product formation, assess purity level by ¹H NMR, and carry out several bioassays. Thus, although improvements are desirable, particularly related to yields, this procedure or variants of it has the potential to serve an important role in rapid library synthesis for screening purposes.

One of the most promising targets for α -hydroxytropolone therapeutics is the HIV RT-associated RNaseH, against which the natural products β -thujaplicinol and manicol have demonstrated IC₅₀ values of 200 nM and 600 nM respectively.¹⁰ RNaseH remains a promising enzymatic target for HIV that is untargeted clinically, and major efforts are underway to identify clinically viable inhibitors of this enzymatic function.¹¹ The solid-phase platform represents a powerful tool to increase the throughput of new α -hydroxytropolone-based leads for HIV RT RNaseH therapeutic development, and thus we sought to evaluate our solid-phase library experimentally in HIV RT RNaseH-associated assays in order to test the assay-ready nature of the compounds (Table 2).

We first measured inhibitory activity using a FRET endpoint to monitor RNaseH activity of HIV-1 RT.¹² Consistent inhibitory activity was observed for the majority of the molecules, with typical IC₅₀ values between 200 nM and 1 μ M. IC₅₀ values of the same compounds made through solid-phase versus solution phase were all within 2–3 fold difference, and are mostly within standard deviation. We next tested the molecules' ability to stabilize the

enzyme against thermal denaturation using differential scanning fluorimetry (ThermoFluor).¹³ All molecules typically increased the melting point of the enzyme by 2–3°C, regardless of associated impurities, and those with lower values (**4d**, **4h**, **4i**) did so regardless of whether prepared in solid or solution phase. Finally, we assessed the molecules' protective effects of the synthetic α -hydroxytropolones in HIV-associated cellular assays.¹⁴ Only three of the molecules showed protective effects, and this trend was consistent across solution and solid-phase synthesized compounds. Collectively, these assays show that minor impurities seen in the samples made via the solid-phase platform do not detrimentally impact the enzymatic or cell-based assays, thus demonstrating the assay-ready nature of the molecules and highlighting the advantages in future screening approaches.

While these proof-of-principle synthetic and biological studies demonstrated the extremely time efficient nature of the process and assay-ready purity of the compounds made, improvements with the system are desirable. For example, while the yields of the process were deemed practical for screening purposes, they are still exceedingly low overall. This can be at least tied to some inefficiency with the 3-component oxidopyrylium cycloaddition, where even in solution phase the top yields achieved to date are in 60–70% range, owing largely to incomplete alcohol exchange. In the solid-phase work, this challenge seems to be exacerbated due to the heterogeneous nature of the reaction. As an example, whereas previous solution-phase work witnessed considerable increases when purified oxidopyrylium dimer was used as the source of the ylide, no yield increases were observed in the solid-phase studies (Scheme 2, reaction A vs. Table 1, entry 8/9).

On the other hand, the use of purified oxidopyrylium dimer during the first step did allow us to easily recover it by simply removing the supernatant and evaporating the solvent. In addition to helping re-obtain the unreacted starting material, this feature also provided a means to effectively monitor incorporation. In reaction A in scheme 2, for example, 16 of the 24 mg of the starting material dimer was re-isolated. Assuming that the remaining 8 mg of material exists on bead as the heterodimer, only about half of that material would then be available for subsequent solid-supported cycloaddition and cleavage. Driven by these results, we increased dimer concentrations to 4 equivalents (8 equivalents based upon monomer), and allowed the incorporation step of the reaction to stir over 9 days at room temperature (Scheme 2, reaction B). We were able to recover 87% of the dimer (104 mg of the 120 mg used), and increase our yields based upon bead loading to 20%. These provide some directions for future optimization work.

In summary, we have leveraged a 3-component oxidopyrylium cycloaddition in the first solid-phase synthesis of α -hydroxytropolones. Given the potential of α -hydroxytropolones as therapeutics for a variety of different diseases, this method will find wide usage in therapeutic development. Continued efforts are underway to improve upon this methodology so that it can meet its full potential.

Acknowledgments

MD and RM are grateful for support from The National Institutes of Health (SC1GM111158), and the Alfred P. Sloan Foundation. TM, JB, JW and SL are supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

Notes and references

1. For lead examples, see: Piettre SR, Ganzhorn A, Hoflack J, Islam K, Hornsperger JM. *J Am Chem Soc.* 1997; 119:3201. Himmel DM, Maegley KA, Pauly TA, Bauman JD, Das K, Dharia C, Clark AD Jr, Ryan K, Hickey MJ, Love RA, Hughes SH, Bergqvist S, Arnold E. *Structure.* 2009; 17:1625–1635. [PubMed: 20004166] Didierjean J, Isel C, Querré F, Mouscadet JF, Aubertin AM, Valnot JY, Piettre SR, Marquet R. *Antimicrob Agents Chemother.* 2005; 49:4884–4894. [PubMed: 16304149] Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen J, Parniak MA, Sarafianos SG. *PLoS Pathogens.* 2013; 9:e1003125. [PubMed: 23349632] Hu Y, Cheng X, Cao F, Huang A, Tavis JE. *Antiviral Res.* 2013; 99:221–229. [PubMed: 23796982] Tavis JE, Wang H, Tollefson AE, Ying B, Korom M, Cheng X, Cao F, Davis KL, Wold WSM, Morrison LA. *Antimicrob Agents Chemother.* 2014; 58:7451–7461. [PubMed: 25267681] For recent reviews, see: Meck C, D'Erasmus MP, Hirsch DR, Murelli RP. *Med Chem Comm.* 2014; 5:842–852. Liu N, Song W, Schienebeck CM, Zhang M, Tang W. *Tetrahedron.* 2014; 70:9281–9305. [PubMed: 25400298]
2. The pKa1 and pKa2 values of 7-hydroxytropolone have been measured as 5.6 and 7.0. See: Martin SF, Follows BC, Hergenrother PJ, Franklin CL. *J Org Chem.* 2000; 65:4509–4514. [PubMed: 10959851]
3. (a) Meck C, Mohd N, Murelli RP. *Org Lett.* 2012; 14:5988–5991. [PubMed: 23167954] (b) Williams YD, Meck C, Mohd N, Murelli RP. *J Org Chem.* 2013; 78:11707–11713. [PubMed: 24171600]
4. For other examples of oxidopyrylium cycloaddition/ ring-opening sequences in troponoid synthesis, see: Zhang M, Liu N, Tang W. *J Am Chem Soc.* 2013; 135:12434–12438. [PubMed: 23930656] Adlington RM, Baldwin JE, Mayweg AVW, Pritchard GJ. *Org Lett.* 2002; 4:3009–3011. [PubMed: 12182611]
5. Hirsch DR, Cox G, D'Erasmus MP, Shakya T, Meck C, Mohd N, Wright GD, Murelli RP. *Bioorg Med Chem Lett.* 2014; 24:4943–4947. [PubMed: 25283553]
6. Lu G, Lomonosova E, Cheng X, Moran EA, Meyers MJ, Le Grice SFJ, Thomas CJ, Jiang JK, Meck C, Hirsch DR, D'Erasmus MP, Suyabatmaz DM, Murelli RP, Tavis JE. *Antimicrob Agents Chemother.* 2015; 59:1070–1079. [PubMed: 25451058]
7. (a) Ireland PJ, Tavis JE, D'Erasmus MP, Hirsch DR, Murelli RP, Cadiz MM, Patel BS, Gupta AK, Edwards TC, Korom M, Moran EA, Morrison LA. *Antimicrob Agents Chemother.* 2016; 60:2140–2149. [PubMed: 26787704] (b) Masaoka T, Zhao H, Hirsch DR, D'Erasmus MP, Meck C, Varnado B, Gupta A, Meyers MJ, Baines J, Beutler JA, Murelli RP, Tang L, Le Grice SFJ. *Biochemistry.* 2016; 55:809–819. [PubMed: 26829613]
8. D'Erasmus MP, Meck C, Lewis CA, Murelli RP. *J Org Chem.* 2016; 81:3744–3751. [PubMed: 27018974]
9. For seminal work on the intermolecular oxidopyrylium cycloaddition, see: Wender PA, Mascarenas JL. *Tetrahedron Lett.* 1992; 33:2115–2118.
10. (a) Chung S, Himmel DM, Jiang JK, Wojtak K, Bauman JD, Rausch JW, Wilson JA, Beutler JA, Thomas CJ, Arnold E, Le Grice SFJ. *J Med Chem.* 2011; 54:4462–4473. [PubMed: 21568335] (b) Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, Parniak MA, Crouch RJ, McMahon JB, Beutler JA, Le Grice SFJ. *Nucleic Acid Res.* 2005; 33:1249–1256. [PubMed: 15741178]
11. For a review, see: Cao L, Song W, De Clercq E, Zhan P, Liu X. *Curr Med Chem.* 2014; 21:1956–1967. [PubMed: 24438523]
12. Parniak MA, Min K-L, Budihas SR, Le Grice SFJ, Beutler JA. *Anal Biochem.* 2003; 322:33–39. [PubMed: 14705777]
13. Lavinder JJ, Hari SB, Sullivan BJ, Magliery TJ. *J Am Chem Soc.* 2009; 131:3794–3795. [PubMed: 19292479]
14. Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH, Boyd MR. *J Natl Cancer Inst.* 1989; 81:577–86. [PubMed: 2495366]

Figure 1.

(A) α -Hydroxytropolone drawn in the tropylium resonance and dianionic form, illustrating its favourable metal group-binding features and (B) Overview of oxidopyrylium cycloaddition/ring-opening route to α -hydroxytropolones.

Figure 2.

(a) Overview of operation through which α -hydroxytropolones were made through the use of solid-phase intermediate. (b) Relevant oxidopyrylium heterodimers and homodimers. (c) Common impurities observed along with products made on solid-phase

Scheme 1.

(a) Previously described 3-component oxidopyrylium cycloaddition and application to α -hydroxytropolone synthesis, and (b) an overview of the solid-phase platform described in the current manuscript.

Scheme 2.

Solid-phase synthesis employing purified oxidopyrylium dimer **6a**.

Reaction conditions. (a) **Reaction A.** Polystyrene benzyl alcohol, **6a** (0.75 equiv, 1.5 equiv based on monomer, 66% recovered), CH_2Cl_2 , 60°C, 12 hr. **Reaction B.** Polystyrene benzyl alcohol, **6a** (4 equiv, 8 equiv based on monomer, 87% recovered), CH_2Cl_2 , 60°C, 12 hr. (b) Ethyl propiolate (~25 equivalents), neat, 100°C, 1.5 hr. (c) TfOH (4 equiv.), CH_2Cl_2 , rt, 30 min.

Table 1

Select Results from Solid-Phase Synthesis

Entry	Alkyne	Time ^b	Yield (4:7:8)
1	R = COMe	1.5 hr	8% 4a (9:1:0)
2	R = COMe	2 hr	7% 4a
3 ^c	R = COMe	2 hr	4% 4a (9:1:0)
4 ^a	R = COCy	2 hr	11% 4b (15:1:4)
5 ^a	R = CPh	2 hr	22% 4c (1:0:1)
6 ^{a,c}	R = CPh	2 hr	6% 4c (5:0:1)
7 ^a	R = CO(4-Ph)Ph	3 hr	9% 4d (1:0:1)
8	R = CO ₂ Et	1.5 hr	7% 4e
9	R = CO ₂ Et	1.5 hr	9% 4e
10 ^c	R = CO ₂ Et	1.5 hr	4% 4e
11	R = CO ₂ Me	1.5 hr	6% 4f
12 ^c	R = CO ₂ Me	1.5 hr	6% 4f
13	R = Ph	4.5 hr	7% 4g (9:1:0)
14	R = Ph	5.5 hr	13% 4g (20:1:0)
15 ^c	R = Ph	5.5 hr	6% 4g (5:1:0)
16	R = 4-CF ₃ Ph	4.5 hr	11% 4h (4:1:0)
17	R = 4-CF ₃ Ph	5.5 hr	6% 4h (4:1:0)
18	R = 1-Npth	4.5 hr	7% 4i (5:1:0)
19	R = 1-Npth	5.5 hr	6% 4i (15:1:0)
20	DMAD ^d	1 hr	10% 8j

^aDichloromethane and solutes not removed prior to addition of alkyne.

^bTime for step 2.

^cReaction run at twice the scale of prior run.

^dDMAD = Dimethyl acetylenedicarboxylate.

Table 2

Synthetic α -Hydroxytropolones in HIV RT RNaseH-associated assays.

Compound	HIV RT RNaseH Assays		Cell-Based Assays	
	Inhibition IC ₅₀ (μM)	ThermoFluor T _m (°C)	Antiviral EC ₅₀ (μM)	Cytotoxicity CC ₅₀ (μM)
β-thujaplicinol	0.20 (± 0.03)	2.34	n.p.	2.3
manicol	0.6	n.a.	n.p.	13.6
4a	(Solid)	0.57 (± 0.07)	2.3 (± 0.8)	<50%, 2.8, 5.2
	(Solution)	0.29 (± 0.11)	2.9 (± 0.2)	7.7, 8.2, 24 20, 21
4b	(Solid)	0.52 (± 0.22)	2.0 (± 0.4)	n.p., n.p.
	(Solution)	0.21 (± 0.14)	2.4 (± 0.1)	2.3, 3.1 2.7, 7
4c	(Solid)	0.32 (± 0.12)	2.5 (± 0.1)	n.p., n.p., n.p.
	(Solution)	0.22 (± 0.07)	2.9 (± 0.1)	2.6, 6.6, 8.8 7.2, 8.8
4d	(Solid)	1.0 (± 0.4)	1.7 (± 0.1)	n.p., n.p.
	(Solution)	0.59 (± 0.20)	1.9 (± 0.7)	0.14, 0.97 0.1, 0.83
4e	(Solid)	0.54 (± 0.13)	2.9 (± 0.3)	<50%, <50%
	(Solution)	0.25 (± 0.07)	2.4 (± 0.1)	8.5, 9.7 22, 22
4f	(Solid)	0.44 (± 0.24)	2.9 (± 0.4)	2.2, <50%, 4.2
	(Solution)	0.16 (± 0.06)	2.7 (± 0.4)	5.4, 6.2, 11 15, 15
4g	(Solid)	0.25 (± 0.08)	2.2 (± 0.3)	n.p., n.p., n.p.
	(Solution)	0.39 (± 0.04)	1.5 (± 0.2)	6.4, 7, 5.6 2.5, 3.7
4h	(Solid)	0.80 (± 0.30)	0.2 (± 0.2)	n.p., n.p., n.p.
	(Solution)	1.1 (± 0.7)	0.9 (± 0.6)	2.3, 7.1, 2.7 2.2, 6.7
4i	(Solid)	0.56 (± 0.19)	1.0 (± 0.8)	n.p., n.p., n.p.
	(Solution)	0.26 (± 0.06)	1.5 (± 1.0)	2.1, 2.4, 5.4 3.3, 6.7

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Natural product assay data, with exception of ThermoFluor, reported previously (ref 10a). 'Solid' refers to molecules made on solid-phase without any purification other than an aqueous wash, and 'Solution' refers to higher purity molecules made through solution-phase synthesis. Enzymatic assays of synthetic α -hydroxytropolones shown as the average of 2 or 3 triplicate runs $\pm$ standard deviation. Cell-based assays shown as duplicate runs using α -hydroxytropolones made on solid-support, run alongside the pure molecules made in solution phase. '<50%', indicates observed protective effects that can't be assigned EC₅₀ values because they don't exceed 50% cell viability. For objectivity, these are defined as those that display 35% – 50% cell viability at optimal concentrations. 'n.p.' indicates no protective effects (<35% cell viability throughout assay). 'na' indicates not available. For select examples, α -hydroxytropolones made on solid-support from a separate trial run were tested to assess batch variability, and are the third set of data where applicable